NEW YORK, May 12, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
Crohn's disease: future treatment scenarios and opportunities
http://www.reportlinker.com/p0490895/Crohn's-disease-future-treatment-scenarios-and-opportunities.html?utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology
Changes in therapeutic strategies for Crohn's disease are set to have a profound impact on its treatment landscape, exacerbating current and generating new treatment challenges for doctors, while presenting new and potentially lucrative opportunities for current and future market players. Sociable Pharma conducted in-depth primary research in the US and across Europe with six key opinion leaders to understand how these changes will impact therapy use in the future. We also gauged opinion during the European Crohn's & Colitis Organisation's (ECCO) Annual Congress on the impact that new clinical data for existing and pipeline products will have on treatment strategies employed by inflammatory bowel disease specialists.
HIGHLIGHTS
Identifies the latest treatment trends in Crohn's disease, including the growing importance of "top-down" treatment strategies for moderate-to-severe Crohn's disease
Based on key opinion leader interviews in the US and Europe, as well as the ECCO 2011 conference, supplemented with extensive secondary research on medical evidence and guidelines
Identifies commercial opportunities in Crohn's disease treatment including:
1. Targeting patients naïve to anti-TNF therapies with novel oral inhibitors
2. Combination therapies with helminth in mild-to-moderate disease
3. Improved localized release of corticosteroids to reduce systemic side effects
Assesses future scenarios for Crohn's disease therapies, including:
1. Migration of anti-TNF therapies to new treatment settings
2. Impact of tailored induction and maintenance regimens
3. Future use of antibiotics, probiotics and helminth in mild-to-moderate disease
Executive Summary
Scope of analysis & methodology
Commercial opportunities
Corticosteroids
Aminosalicylates
Immunomodulators
Anti-TNF therapies
Antibiotics
Probiotics
Helminth therapy
New biologics
Novel oral therapies
Future scenarios
Crohn's Disease Treatment Map
Companies mentioned
AstraZeneca
Prometheus
Forest
UCB Pharma
Ferring
Shire
Warner Chilcott
Salix
Alaven
Axcan
Pfizer
Almirall
GSK
Centocor
Merck
TOA Probiotics
Teva
Genzyme
Cellerix
Ovamed
Asphelia
To order this report:
Pathology Industry: Crohn's disease: future treatment scenarios and opportunities
Pathology Business News
More Market Research Report
Check our Company Profile, SWOT and Revenue Analysis!
Nicolas BombourgReportlinkerEmail: [email protected]US: (805)652-2626Intl: +1 805-652-2626
SOURCE Reportlinker
Advertisement
Crohn's disease: future treatment scenarios and opportunities
http://www.reportlinker.com/p0490895/Crohn's-disease-future-treatment-scenarios-and-opportunities.html?utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology
Advertisement
Changes in therapeutic strategies for Crohn's disease are set to have a profound impact on its treatment landscape, exacerbating current and generating new treatment challenges for doctors, while presenting new and potentially lucrative opportunities for current and future market players. Sociable Pharma conducted in-depth primary research in the US and across Europe with six key opinion leaders to understand how these changes will impact therapy use in the future. We also gauged opinion during the European Crohn's & Colitis Organisation's (ECCO) Annual Congress on the impact that new clinical data for existing and pipeline products will have on treatment strategies employed by inflammatory bowel disease specialists.
HIGHLIGHTS
Identifies the latest treatment trends in Crohn's disease, including the growing importance of "top-down" treatment strategies for moderate-to-severe Crohn's disease
Based on key opinion leader interviews in the US and Europe, as well as the ECCO 2011 conference, supplemented with extensive secondary research on medical evidence and guidelines
Identifies commercial opportunities in Crohn's disease treatment including:
1. Targeting patients naïve to anti-TNF therapies with novel oral inhibitors
2. Combination therapies with helminth in mild-to-moderate disease
3. Improved localized release of corticosteroids to reduce systemic side effects
Assesses future scenarios for Crohn's disease therapies, including:
1. Migration of anti-TNF therapies to new treatment settings
2. Impact of tailored induction and maintenance regimens
3. Future use of antibiotics, probiotics and helminth in mild-to-moderate disease
Executive Summary
Scope of analysis & methodology
Commercial opportunities
Corticosteroids
Aminosalicylates
Immunomodulators
Anti-TNF therapies
Antibiotics
Probiotics
Helminth therapy
New biologics
Novel oral therapies
Future scenarios
Crohn's Disease Treatment Map
Companies mentioned
AstraZeneca
Prometheus
Forest
UCB Pharma
Ferring
Shire
Warner Chilcott
Salix
Alaven
Axcan
Pfizer
Almirall
GSK
Centocor
Merck
TOA Probiotics
Teva
Genzyme
Cellerix
Ovamed
Asphelia
To order this report:
Pathology Industry: Crohn's disease: future treatment scenarios and opportunities
Pathology Business News
More Market Research Report
Check our Company Profile, SWOT and Revenue Analysis!
Nicolas BombourgReportlinkerEmail: [email protected]US: (805)652-2626Intl: +1 805-652-2626
SOURCE Reportlinker
